Answers are grounded in this paper and cite their sources.
Obesity has emerged as a major global chronic disease and is now widely recognized as a complex, relapsing metabolic disorder rather than merely the result of excessive caloric intake or insufficient physical activity. Its prevalence has increased markedly worldwide over recent decades, contributing to a substantial burden of obesity-related complications, including type 2 diabetes mellitus, cardiovascular disease, hypertension, dyslipidemia, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, osteoarthritis, several malignancies, and reduced quality of life. The recognition of obesity as a chronic disease has shifted the therapeutic paradigm from short-term weight reduction toward sustained, long-term disease management. Lifestyle modification, including dietary intervention, increased physical activity, and behavioural strategies, remains the foundation of obesity management. However, many individuals are unable to achieve or maintain clinically meaningful weight loss with lifestyle interventions alone, highlighting the need for effective pharmacological therapies. The therapeutic landscape has been substantially transformed by incretin-based treatments, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and the glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor co-agonist tirzepatide. These therapies have demonstrated considerable efficacy in reducing body weight and improving several metabolic risk factors. Recent drug development has expanded beyond single-receptor agonist toward multi-hormonal therapies, oral smallmolecule GLP-1 receptor agonists, amylin-based agents, and combination regimens. Retatrutide, a triple GIP/GLP1/glucagon receptor agonist, has produced substantial weight reduction in phase 2 clinical studies and represents a promising investigational approach. Orforglipron, an oral non-peptide GLP-1 receptor agonist, may offer an important alternative to injectable therapies and has the potential to improve treatment convenience and accessibility. Other emerging strategies include combinations such as semaglutide with cagrilintide and next-generation multi-receptor agonists designed to target complementary metabolic pathways. Despite these advances, several challenges continue to influence the long-term management of obesity. Gastrointestinal adverse effects, treatment discontinuation, weight regain following pharmacological withdrawal, uncertainties regarding long-term safety, high treatment costs, limited accessibility, and healthcare-system capacity remain important considerations. Future therapeutic development is therefore focused not only on achieving greater weight reduction but also on improving treatment tolerability, durability, accessibility, and long-term cardio metabolic outcomes. This narrative review examines the evolution of obesity management, established pharmacological therapies, and emerging treatment strategies, with particular emphasis on their mechanisms of action, clinical efficacy, limitations, and potential role in the long-term management of obesity as a chronic disease.
No takes yet. Share an insight, caveat, or question.
Bhupendra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: